A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
You are being asked to be in this study because you have epilepsy and you take epilepsy medication. Aquestive Therapeutics (the study Sponsor) has begun a research study of an investigational drug called Diazepam Buccal Soluble Film or DBSF as a possible treatment for patients with epilepsy. An investigational drug …
Preterm birth is the primary driver of perinatal morbidity and mortality affecting approximately 11% of all newborns in the United States.1 Of the 4 million neonatal deaths that occur annually around the world, more than a quarter are the result of preterm birth.2 A short cervix by ultrasound has been …
The BRCA Founder Outreach (BFOR) Study is a new research initiative. BFOR seeks to increase access to testing for one of the most common tests for hereditary cancer, BRCA genetic mutations. These mutations of BRCA genes are associated with greater risks for several types of cancer, including breast, ovarian, and prostate …
WIRB will be the Main IRB and Penn will be the relying IRB. NYHA Class I-II patients are now eligible for CRT following the MADIT CRT study, and there are no prior data for these patients using the SmartDelay feature. Furthermore, in the intervening seven years since the SMART AV …
Non-invasive transcranial magnetic stimulation (TMS) is now FDA-approved for the treatment of major depressive disorder (MDD). However, there is growing evidence that the targeting strategy for delivering TMS treatment would yield superior clinical outcomes if it were more tailored to individual neuroanatomy. In this study, we plan to examine whether …
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will …
This is an open-label, non-randomized trial that will be conducted at three clinical sites. The subject population will be patients undergoing transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) at Thomas Jefferson University, The University of California, San Diego, and University of Pennsylvania. Patients will receive a contrast-enhanced …
This is a Phase II single-arm, single-site, open label clinical trial with r/r HL patients, aimed to determine whether a RadVax approach using low-dose RT added to nivolumab can improve response among patients who do not achieve a CR to nivolumab alone. The long-term goal is to develop an effective …
The trial involves an investigational device (not approved by the FDA) for subjects who have an aneurysm (bulge), dissection (tear) or a penetrating ulcer (bubble) of the descending aorta that involve an artery (main blood vessel in your body). The subject must need to have one of their blood vessels …